Glucagon: Counter-Regulatory Hormone, Metabolic Mobilisation and Fasting Physiology
Glucagon is the body’s principal counter-regulatory hormone to insulin. Secreted by pancreatic alpha cells, it plays a critical role in maintaining blood glucose levels during fasting, exercise and metabolic stress. While insulin promotes nutrient storage, glucagon mobilises energy reserves, ensuring that vital organs, particularly the brain, have a constant supply of glucose. Its actions extend beyond carbohydrate metabolism to include lipid and protein pathways, making glucagon an essential component of whole-body energy balance.
What You Need to Know
Glucagon is a peptide hormone secreted by pancreatic alpha cells and plays a central role in maintaining blood glucose during fasting and physiological stress. Whereas insulin promotes nutrient storage in the fed state, glucagon acts to mobilise energy reserves when glucose availability is limited. Together, these two hormones form a tightly regulated system that allows the body to switch smoothly between fed and fasting metabolism.
Glucagon secretion increases in response to several key physiological signals:
Falling blood glucose levels
Sympathetic nervous system activation
Elevated circulating amino acids
Certain gastrointestinal hormones
The primary target organ for glucagon is the liver. Binding of glucagon to hepatic receptors stimulates glycogen breakdown and gluconeogenesis, leading to increased release of glucose into the circulation. During prolonged fasting, glucagon also promotes lipid mobilisation and ketone body formation, providing alternative energy substrates for peripheral tissues and the brain. Through these actions, glucagon supports glucose availability and metabolic stability when dietary intake is reduced.
Because glucagon’s effects oppose those of insulin, the balance between the two hormones determines the body’s overall metabolic state. Disruption of glucagon secretion or signalling contributes to metabolic instability, including inappropriate glucose release in diabetes or impaired counter-regulation during hypoglycaemia. Understanding glucagon’s role alongside insulin is essential for interpreting normal fasting physiology and the pathophysiology of glucose disorders.
Beyond the Basics
Alpha-cell structure and regulatory context
Alpha cells are located predominantly at the periphery of pancreatic islets, a position that places them in close contact with the islet microvasculature and exposes them to both circulating signals and local paracrine influences. This arrangement is functionally important, as alpha cells integrate information from blood glucose levels as well as hormones released by neighbouring beta and delta cells. Unlike beta cells, which are activated by rising glucose, alpha cells increase activity when glucose levels fall and are inhibited when local concentrations of insulin and somatostatin are high.
Regulation of glucagon secretion therefore depends on both direct glucose sensing and local islet signalling. When blood glucose falls, insulin secretion decreases, removing an important inhibitory signal and allowing glucagon release to rise. During exercise, illness, or acute stress, sympathetic nervous system activation further stimulates glucagon secretion, even when glucose levels are not critically low. This integration ensures that hepatic glucose output can increase rapidly when energy demand rises.
Mechanisms of glucagon secretion
Glucagon secretion is triggered by changes in alpha-cell metabolism that occur during low glucose availability. Reduced glucose uptake leads to lower ATP production, which alters the activity of ATP-sensitive potassium channels and promotes membrane depolarisation. This depolarisation opens voltage-gated calcium channels, allowing calcium influx that triggers exocytosis of glucagon-containing granules.
Amino acids are also potent stimulators of glucagon release. After protein-rich meals, rising amino acid levels stimulate alpha cells, ensuring that hepatic glucose production increases to prevent hypoglycaemia. This response is particularly important when carbohydrate intake is low, as it maintains glucose availability for glucose-dependent tissues such as the brain. The coupling of amino acid sensing to glucagon secretion highlights glucagon’s role in coordinating protein metabolism with glucose homeostasis.
Hepatic metabolic actions
The liver is the primary target organ for glucagon and the site where its metabolic effects are most pronounced. Glucagon binds to a G-protein-coupled receptor on hepatocytes, activating adenylate cyclase and increasing intracellular cyclic AMP levels. This signalling cascade activates protein kinase A, which rapidly alters enzyme activity through phosphorylation.
These changes promote glycogen breakdown, stimulate gluconeogenesis from substrates such as amino acids and lactate, and inhibit glycolysis within the liver. By suppressing hepatic glucose utilisation while increasing glucose production, glucagon ensures that glucose is released into the circulation rather than consumed locally. This mechanism is central to maintaining blood glucose levels between meals and during overnight fasting.
Lipid mobilisation and ketone production
Beyond its effects on glucose metabolism, glucagon plays an important role in lipid mobilisation during prolonged fasting. In adipose tissue, glucagon supports lipolysis by activating hormone-sensitive lipase, increasing the release of free fatty acids into the circulation. These fatty acids provide an alternative energy source for peripheral tissues and reduce reliance on glucose.
Within the liver, glucagon enhances beta-oxidation of fatty acids and promotes ketone body production. Ketones become an increasingly important fuel for the brain when glucose availability is limited, particularly during prolonged fasting or starvation. This metabolic shift preserves muscle protein by reducing the need for gluconeogenesis from amino acids, highlighting glucagon’s role in long-term energy conservation.
Integration with insulin and incretin hormones
Glucagon and insulin function as opposing but complementary regulators of metabolism. Rather than acting independently, their relative concentrations determine whether the body is in a fed, fasting, or stress-adapted state. Insulin suppresses glucagon release after meals, while falling insulin levels during fasting allow glucagon secretion to rise.
Incretin hormones, particularly glucagon-like peptide-1, further modulate this balance by suppressing glucagon secretion in the postprandial period. This suppression limits inappropriate hepatic glucose output after eating. In type 2 diabetes, impaired incretin signalling and reduced alpha-cell sensitivity to insulin contribute to inappropriate glucagon secretion, worsening hyperglycaemia. Understanding these interactions reinforces why dysregulated glucagon action plays a significant role in metabolic disease alongside insulin dysfunction.
Clinical Connections
Abnormal glucagon secretion or impaired counter-regulation has important clinical consequences because glucagon is the primary hormone responsible for preventing hypoglycaemia during fasting and stress. Disturbances in glucagon action often become apparent through unstable glucose control rather than isolated symptoms, particularly in people with diabetes or pancreatic disease.
In clinical practice, glucagon-related disorders tend to present in a small number of recognisable patterns:
Excess glucagon secretion contributing to hyperglycaemia
Impaired glucagon responses leading to hypoglycaemia
Therapeutic use of glucagon to raise blood glucose or relax smooth muscle
Excess glucagon secretion contributes significantly to hyperglycaemia in diabetes by stimulating hepatic glucose output even when insulin levels are adequate or elevated. This inappropriate glucose release worsens fasting and postprandial hyperglycaemia and helps explain why glucose control may remain poor despite insulin therapy. In rare cases, glucagonomas—tumours arising from pancreatic alpha cells—cause marked glucagon excess. These tumours produce severe hyperglycaemia, weight loss, muscle wasting, and a distinctive skin condition known as necrolytic migratory erythema, reflecting the catabolic effects of sustained glucagon action.
In contrast, inadequate glucagon responses impair the body’s ability to recover from falling blood glucose levels. This is particularly relevant in advanced diabetes, where repeated hypoglycaemic episodes blunt normal counter-regulatory hormone release, and after bariatric surgery, where altered nutrient delivery and hormonal signalling disrupt alpha-cell responses. Recurrent hypoglycaemia in these settings reflects failure of glucagon-mediated hepatic glucose production rather than insulin excess alone.
Glucagon is also used therapeutically because of its rapid metabolic and smooth muscle effects. It is administered to treat severe hypoglycaemia when oral glucose is not possible, relying on its ability to stimulate hepatic glycogen breakdown. Glucagon is also used in certain gastrointestinal emergencies, as it relaxes smooth muscle and can facilitate procedures involving the oesophagus or bowel.
Concept Check
How does the structure and location of alpha cells support their role in glucose regulation
Why do amino acids stimulate glucagon secretion after a protein-rich meal
How does glucagon increase glucose availability during fasting
Why is glucagon important for ketone body production
How does dysregulated glucagon secretion contribute to hyperglycaemia in type 2 diabetes